and detected it in 47% (42/89) of the samples from mainland China, 29% (10/35) of the samples from Southeast Asia, 13% (29/231) of the samples from Korea, 2.7% (13/477) of the samples from Japan, 4 .8% (10/209) of the samples from North America and 1.7% (4/230) of the samples from Europe. 6 Collectively, these data indicate that the AA signature is closely associated with HCCs in Asia. Thereafter, AA has been widely discussed and has rapidly become the focus of public debate again.
| COMMENTARY

| Attitudes in and measures taken by different countries regarding AA
Based on the incident that occurred in Belgium, the French Ministry of Health banned the sale of drugs containing AA in 1994. In 1999, the British Committee on Safety of Medicines (CSM) suggested that the use of botanical drugs containing AA be banned immediately. 7 In October 2000, the European Agency for the Evaluation of
Medicinal Products issued a position paper that warned European Union Member States "to take steps to ensure that the public is protected from exposure to aristolochic acids arising from the deliberate use of Aristolochia species or as a result of confusion with other botanical ingredients." 8 On 2 November 2000, the World Health Organization (WHO) issued a similar warning in drug communications. Various countries, including Malaysia, Spain, Japan, Egypt, Austria and the Philippines, have followed suit. 9 In 2001, the US FDA advised consumers to stop using products containing AA, and the sale of AA-containing botanical products has also been prohibited in several other countries, including Canada, New Zealand, Australia and many Asian countries. 2 In addition, AA exposure has been fre- 
| Mechanisms of AA-induced nephrotoxicity and carcinogenicity
Recent studies have investigated the mechanisms underlying the nephrotoxicity and carcinogenicity of AA. 15 The dose of AA might lead to a toxic reaction. In addition to differences in the accumulated dose of AA and the duration of AA intake, individual differences in the activities of enzymes that catalyse the biotransformation of AA could be responsible for the observed discrepancy in susceptibility levels. Thus, the identification of the enzymes involved in AA metabolism is of particular relevance. 2 In the liver, the AA mixture is metabolized under anaerobic conditions to the corresponding aristolactam I and II, whereas under aerobic conditions, the only metabolite obtained is the O-demethylated derivative aristolochic acid Ia (AA Ia), which is a biotransformation product from aristolochic acid I (AA I). AA I is considered to be responsible for the nephrotoxic and carcinogenic effects of AA. 22 The most important human, mouse and rat enzyme that activates AA I in the hepatic and renal cytosolic subcellular fraction is NAD(P)H:quinone oxidoreductase (NQO1), but hepatic microsomal cytochrome P450
(CYP) 1A1/2 and renal microsomal NADPH:CYP reductase (POR)
have also been shown to reduce AA I. Moreover, genetic polymorphisms, drugs, smoking habits and environmental chemicals have been identified as important factors that influence the expression levels and activities of these enzymes and might thus explain the interindividual differences in susceptibility to AA toxicity. 10 Third, the liver injury induced by AA is not associated with the A-T-specific mutation in the p53 gene. After the oral administration of AA I for at least one week, Bara observed changes in TP53 knock-in mice and canine livers that were associated with overexpression of the c-Myc oncoprotein and the oncofetal RNA-binding protein Lin28B. The miRNAs that encode the signal transduction proteins interleukin (IL)-6 and NF-κB are also apparently involved in hepatocarcinogenesis. 23 Jin fed AA I at a dose of 3 mg/kg/d to beagle canines for 10 days and found that short-term AA I exposure could lead to hepatic premalignant alterations associated with the upregulation of c-Myc and Lin28B. 24 Rossiello reported that rats administered AA both orally and via injection at a dose of 10 mg/kg/d for 3-6 months did not exhibit induction of compensatory liver cell proliferation. However, rats injected with AA and 1% orotic acid (for pH regulation) at a dose of 10 mg/kg/d for 10 weeks displayed glutathione-S-transferase 7-7-positive hepatic foci and nodules, which promoted the carcinogenic process in the livers. 25 Li T concluded that both c-Myc and Lin28B could be considered markers of carcinogenesis in liver-like tissue due to AA I exposure. 26 None of these experiments indicate that AA-induced liver injury is caused by A-Tspecific mutations.
Fourth, the causes of liver cancer have been reported to be chronic hepatitis (B, C), aflatoxin contamination (rice and peanut), alcoholic hepatitis and nonalcoholic steatohepatitis. Chronic hepatitis and cirrhosis are considered the main causes of the high incidence of liver cancer (Table 1) . 27, 28 Based on the mutation rate, the main cause of liver cancer in China should now be AA, which is obviously not consistent with the actual scenario.
Fifth, the article has presented some further problems. The initial finding was that the proportion of AA-related characteristic mutations is high in liver cancer patients from only countries in Asia.
However, no direct evidence confirming that patients with the characteristic mutational spectrum had consumed AA or related preparations was presented. In addition, the content, dosage and course of AA were not investigated, and the presence of AA and its derivatives in the sample was not detected, demonstrating a lack of epidemiological evidence. 30 In addition, the published data for the 1,400 HCC cases used in the study were not ideal. Interestingly, a high percentage of the cases of AA signature was observed in only a small group (approximately 100 cases), whereas low percentages were found in a large group (200-500 cases). The percentage of AA signatures in
Chinese HCCs is questionable due to the large population and vast regional diversity of China: the cases included in the article were selected from a relatively small group from Hong Kong (88 cases), and the 98 cases from Taiwan were sampled from only two hospitals. 31 The representativeness of this sampling method is also questionable.
The reason why the mutation rate in Japan, which is also an Asian country with high AA exposure, is much lower than that in other countries and regions remains to be found. The proportion of AAspecific mutation sites in Japanese liver cancer patients is only 2.7%, which is notably lower than that in patients from other Asian countries and regions and is even lower than that in patients from North America (4.8%). However, the presence of bias with respect to case selection remains to be verified. 32 Moreover, the article lacks a com- 
| Medical philosophy regarding the toxicity of AA
Some Asian populations believe that traditional herbal medicines are more natural and safer than Western medicines. 34 Although many countries have banned the sale of products containing AA, some herbal products containing Aristolochia species continue to be sold on the Internet. 35 Therefore, it is important to educate the public, particularly Asians, about the benefits and dangers of both herbal and Western medicines.
Every drug is toxic to a certain extent. Some researchers believe that traditional Chinese medicine has its own method of detoxification, which includes compatibility, processing technologies and other means, to effectively inhibit the toxicity of AA. 36 "Combat poison with poison" is a special feature of Chinese medicine. Arsenic is known to be poisonous but exerts unique effects in the treatment of leukaemia. 37 Paracetamol is recognized as a chemical that causes liver damage but exhibits remarkable efficacy as an antipyretic and analgesic. 38 Although there are reports of liver cancer caused by AA, the reports do not exclude metastatic cancer, different pH condi- affecting the synthesis of other pharmaceutical ingredients. 40 It is believed that these efforts will contribute to the attenuation and detoxification of AA in traditional Chinese medicine.
| WHAT IS NE W AND CON CLUS I ON
To ultimately control the toxicity of AA, we should further study the AA content in related medicinal materials and preparations to determine the minimum effective and toxic doses. We should also study The use of preparations containing AA remains controversial.
Thus, this issue warrants further discussion, and a large number of basic and clinical experiments must be conducted. In short, AA should be treated rationally before any definite conclusion is drawn.
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